SCHEMBL2494015

SCHEMBL2494015

Cn1ncnc1-c1nccs1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDPK1 O15530 1/20 0.38
▸ RAB9A P51151 3/20 0.36
▸ NPC1 O15118 2/20 0.36
▸ RECQL P46063 2/20 0.36
▸ PKM P14618 1/20 0.36
▸ HSP90AA1 P07900 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ TSHR P16473 2/20 0.35
▸ ADRB2 P07550 1/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ KDM4A O75164 1/20 0.35
▸ ABL1 P00519 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ POLB P06746 1/20 0.35
▸ HSP90AB1 P08238 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ CDH1 P12830 1/20 0.35
▸ TCF4 P15884 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21233278 0.72 CYP11B2 (0.40) PDPK1RAB9ANPC1RECQLPKM
SCHEMBL15557371 0.72 RAB9A (0.42) PDPK1RAB9ANPC1RECQLPKM
SCHEMBL12320187 0.71 ADORA2A (0.43) PDPK1RAB9ANPC1RECQLPKM
SCHEMBL22728125 0.69 NPC1 (0.40) PDPK1RAB9ANPC1RECQLPKM
SCHEMBL28567318 0.69 COMT (0.43) PDPK1RAB9ANPC1RECQLPKM
SCHEMBL12681315 0.69 SCN9A (0.38) RAB9ANPC1RECQLHSP90AA1ALDH1A1
SCHEMBL102331 0.68 PDPK1 (0.59) PDPK1RAB9AHSP90AA1ALDH1A1TSHR
SCHEMBL15219345 0.68 NPC1 (0.39) PDPK1RAB9ANPC1RECQLPKM
SCHEMBL4946512 0.67 NPC1 (0.38) PDPK1RAB9ANPC1RECQLPKM
SCHEMBL21241203 0.67 PDE10A (0.40) PDPK1RAB9ANPC1RECQLPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030304-B2 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY (US) 2011-10-04 — — US disclosed
EP-2094709-B1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS LILLY CO ELI (US) 2010-09-15 — — EP disclosed
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists ELI LILLY AND COMPANY 2010-09-02 — — US disclosed
EP-2094709-A1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2009-09-02 — — EP disclosed
WO-2008036579-A1 THIAZOLE PYRAZOLOPYRIMIDINES AS CRF1 RECEPTOR ANTAGONISTS ELI LILLY AND COMPANY (US) 2008-03-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222339-A1 Thiazole pyrazolopyrimidines CRF1 receptor antagonists CRHR1, CRH, CRHR2 PDPK1 568/4885RAB9A 2194/4885NPC1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback